Novo Nordisk NVO has stumbled through 2025, with its shares down 41.5% year to date despite finally resolving U.S. supply constraints for its semaglutide-based GLP-1 blockbusters — Ozempic for type II ...

Companies like Cigna and CVS are promising simpler prices, but the behind-the-scenes system remains complex.

Can Novo Nordisk get its comeback going in 2026? Let's discuss two things that could materialize for the company next year ...

A proposed new federal law could provide some competitive guardrails for the company's most important product.

The price/sales TTM, EV/Sales TTM, and EV/EBITDA TTM of Novo, as compared to its peers, repeat substantially the same story ...

Novo Nordisk A/S said its high-dose version of blockbuster Wegovy has been cleared by the European Union’s drug advisory board, opening the way for use of a shot that delivers more weight loss than ...

For 2026, the plan features significantly lower out-of-pocket costs for members who use the plan’s “narrow network” that ...